FIELD: biotechnology.
SUBSTANCE: present invention relates to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) directed against a B cell maturation antigen (BCMA). Present invention also discloses host cells, such as T cells or natural killer (NK cells) expressing CAR, and refers to methods for destroying multiple myeloma cells using these cells.
EFFECT: present invention makes it possible to expand the arsenal of agents for the treatment of multiple myeloma.
22 cl, 9 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS TARGETED B-CELL MATURATION ANTIGEN | 2013 |
|
RU2766608C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2684713C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B-CELLS | 2016 |
|
RU2706582C2 |
| M971 CHIMERIC ANTIGEN RECEPTORS | 2013 |
|
RU2658485C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR THYMIC STROMAL LYMPHOPOIETIN RECEPTOR, AND METHODS FOR USE THEREOF | 2014 |
|
RU2701346C1 |
| CHIMERIC ANTIGEN RECEPTORS AND THEIR PRODUCTION METHODS | 2015 |
|
RU2753965C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| CHIMERIC ANTIGEN RECEPTORS M971 | 2018 |
|
RU2770411C1 |
